Payment overview · 2025
General Payments
$812.65
38 reported records · 16 companies
Healthcare provider profile · identity verified
Jaime E Estrada, MD
Allopathic & Osteopathic Physicians|Family Medicine · CALEXICO, CA · NPI 1306917661
Verified facts
What the public records show
CMS Open Payments records show Jaime E Estrada, MD received $812.65 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Prolia, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 604 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.08 | 30.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.82 | 19.2% | 14 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $65.36 | 8.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $62.12 | 7.6% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $40.18 | 4.9% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $30.84 | 3.8% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $26.37 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.08 | 3.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.27 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.91 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.29 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.67 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.46 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.13 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.69 | 1.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.38 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $812.65 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $199.99 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.88 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.68 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $87.48 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $75.59 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $65.36 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $62.12 | 2 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $40.18 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 604 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 57 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
57 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
155 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
207 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
604 | 103 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1787 | 477 |
| Amlodipine Besylate | Amlodipine Besylate | 1228 | 298 |
| Omeprazole | Omeprazole | 1143 | 272 |
| Metformin Hcl | Metformin Hcl | 1040 | 284 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1024 | 182 |
| Hydralazine Hcl | Hydralazine Hcl | 702 | 152 |
| Gabapentin | Gabapentin | 685 | 164 |
| Ozempic | Semaglutide | 604 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 587 | 148 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 547 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 522 | 114 |
| Sertraline Hcl | Sertraline Hcl | 497 | 99 |
| Pioglitazone Hcl | Pioglitazone Hcl | 464 | 105 |
| Losartan Potassium | Losartan Potassium | 455 | 117 |
| Montelukast Sodium | Montelukast Sodium | 436 | 99 |
| Lisinopril | Lisinopril | 369 | 104 |
| Alendronate Sodium | Alendronate Sodium | 334 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 333 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 307 | 85 |
| Valsartan | Valsartan | 307 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 302 | 63 |
| Tradjenta | Linagliptin | 296 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 277 | 93 |
| Furosemide | Furosemide | 273 | 69 |
| Mirtazapine | Mirtazapine | 262 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 64 |
| Meloxicam | Meloxicam | 234 | 73 |
| Ezetimibe | Ezetimibe | 221 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 211 | 52 |
| Simvastatin | Simvastatin | 211 | 53 |
| Trulicity | Dulaglutide | 207 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 45 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 174 | 38 |
| Icosapent Ethyl | Icosapent Ethyl | 170 | 36 |
| Metformin Hcl Er | Metformin Hcl | 168 | 37 |
| Carvedilol | Carvedilol | 164 | 38 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 163 | 43 |
| Vascepa | Icosapent Ethyl | 156 | 35 |
| Jardiance | Empagliflozin | 155 | 33 |
| Fenofibrate | Fenofibrate | 139 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 61 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 132 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 127 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 115 | 21 |
| Eliquis | Apixaban | 109 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 99 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 20 |
| Glipizide | Glipizide | 95 | 19 |
| Glimepiride | Glimepiride | 89 | 25 |
| Meclizine Hcl | Meclizine Hcl | 89 | 27 |
| Allopurinol | Allopurinol | 88 | 19 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 85 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 32 |
| Potassium Chloride | Potassium Chloride | 83 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | 18 |
| Finasteride | Finasteride | 82 | 20 |
| Nateglinide | Nateglinide | 82 | 13 |
| Farxiga | Dapagliflozin Propanediol | 80 | 27 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 17 |
| Baclofen | Baclofen | 73 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 72 | 66 |
| Myrbetriq | Mirabegron | 71 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 22 |
| Celecoxib | Celecoxib | 67 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 18 |
| Telmisartan | Telmisartan | 65 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 65 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 15 |
| Linzess | Linaclotide | 62 | 20 |
| Dutasteride | Dutasteride | 60 | 11 |
| Ramipril | Ramipril | 60 | 13 |
| Januvia | Sitagliptin Phosphate | 59 | 14 |
| Prolia | Denosumab | 57 | 36 |
| Enalapril Maleate | Enalapril Maleate | 56 | 13 |
| Famotidine | Famotidine | 56 | 14 |
| Lovastatin | Lovastatin | 54 | 12 |
| Jentadueto | Linagliptin/Metformin Hcl | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 12 |
| Novolog Flexpen | Insulin Aspart | 43 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 41 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 15 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Prednisone | Prednisone | 26 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Procrit | Epoetin Alfa | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 18 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Epogen | Epoetin Alfa | 14 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Celebrex | Celecoxib | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $812.65 · 38 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, EVENITY, FARXIGA, GIVLAARI, ISTURISA, JARDIANCE, Kerendia, Korlym, MOUNJARO, Ozempic, PROLIA, PROSTEP MICA, RECORLEV, Rybelsus, SHINGRIX, Senza, VOQUEZNA, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error